From the publishers of JADPRO

CAR T-Cell Therapy Resource Center

Advertisement

Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma

Last Updated: Friday, July 17, 2026

Ten European experts share their clinical experience regarding optimal bridging therapy selection, efficacy, safety, and outcomes following CAR T-cell therapy. They focus on heavily pretreated patients and emerging options, including bispecific T-cell engagers.

Bone Marrow Transplantation
Advertisement
News & Literature Highlights
Advertisement
Advertisement